IP Library Granted Patent US 7,459,430
Granted Patent B2
US 7,459,430 · App. 11/449,489 · Granted Dec 2, 2008

Methods of using ziconotide to treat overactive bladder

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,459,430
App. No.
11/449,489
Granted
Dec 2, 2008
Kind
B2
Abstract

The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.

Claims (14)

1. A method for treating overactive bladder which comprises administering to an individual in need thereof a therapeutically effective amount of an active agent wherein said agent is Ziconotide (ω-conotoxin MVIIA) or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the active agent is contained within a pharmaceutical formulation.

3. The method of claim 2 , wherein the pharmaceutical formulation is a unit dosage formulation.

4. The method of claim 1 , wherein the active agent is administered on an as-needed basis.

5. The method of claim 1 , wherein the active agent is administered prior to commencement of an activity wherein suppression of the symptoms of overactive bladder would be desirable.

6. The method of claim 5 , wherein the active agent is administered from about 0 to about 3 hours prior to commencement of an activity wherein suppression of said symptoms would be desirable.

7. The method of claim 2 , wherein the formulation is a controlled release dosage formulation.

8. The method of claim 7 , wherein the formulation is a delayed release dosage formulation.

9. The method of claim 7 , wherein the formulation is a sustained release dosage formulation.

10. The method of claim 9 , wherein the sustained release dosage formulation provides drug release over a time period of from about 6 hours to about 8 hours.

11. The method of claim 1 , wherein said overactive bladder is OAB Wet.

12. The method of claim 1 , wherein said overactive bladder is OAB Dry.

13. The method of claim 2 , wherein the pharmaceutical formulation further comprises an additional active agent.

14. The method of claim 13 , wherein the additional active agent is ω- conotoxin GVIA or a salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 25, 2010
From: DYNOGEN PHARMACEUTICALS, INC.
To: EDUSA PHARMACEUTICALS, INC.
Reel/Frame 024879/0568 →